226 related articles for article (PubMed ID: 34958422)
1. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract][Full Text] [Related]
2.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
3. Image intensity histograms as imaging biomarkers: application to immune-related colitis.
Huff DT; Ferjancic P; Namías M; Emamekhoo H; Perlman SB; Jeraj R
Biomed Phys Eng Express; 2021 Sep; 7(6):. PubMed ID: 34534974
[No Abstract] [Full Text] [Related]
4. Assessing immune organs on
Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
[TBL] [Abstract][Full Text] [Related]
5. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
7. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
8. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
12. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
[No Abstract] [Full Text] [Related]
13.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
14. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
[TBL] [Abstract][Full Text] [Related]
15. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic impact of
Tatar G; Alçin G; Sengul Samanci N; Erol Fenercioglu Ö; Beyhan E; Cermik TF
Clin Transl Oncol; 2022 Oct; 24(10):1903-1913. PubMed ID: 35594002
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor-Related Adverse Effects and
Schierz JH; Sarikaya I; Wollina U; Unger L; Sarikaya A
J Nucl Med Technol; 2021 Dec; 49(4):324-329. PubMed ID: 34330805
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
Peisen F; Gerken A; Dahm I; Nikolaou K; Eigentler T; Amaral T; Moltz JH; Othman AE; Gatidis S
PLoS One; 2024; 19(1):e0296253. PubMed ID: 38180971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]